MAGICAL MEDICINE: HOW TO MAKE AN ILLNESS ... - Invest in ME
MAGICAL MEDICINE: HOW TO MAKE AN ILLNESS ... - Invest in ME
MAGICAL MEDICINE: HOW TO MAKE AN ILLNESS ... - Invest in ME
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
227<br />
of 600 participants. Issue 3 of December 2008 states that numbers of recruits had still not reached the target,<br />
so the MRC had granted the Trial team further fund<strong>in</strong>g to allow them to cont<strong>in</strong>ue recruit<strong>in</strong>g until November<br />
2008 to enable them to achieve their target of 600 participants. The PACE Trial Participants’ Newsletter Issue<br />
3 said that because there was a problem with recruit<strong>in</strong>g participants, as well as be<strong>in</strong>g granted more money<br />
by the MRC and more time to achieve the set recruitment levels, it had been decided that an additional Trial<br />
Centre should be opened at Frenchay Hospital, Bristol (which had begun recruit<strong>in</strong>g <strong>in</strong> April 2007).<br />
There was undoubtedly a problem with recruitment and the M<strong>in</strong>utes of the PACE Trial Steer<strong>in</strong>g Committee<br />
held on 22 nd April 2004 record that recruitment estimates “need to be reviewed. It was particularly noted that<br />
it may be worth tra<strong>in</strong><strong>in</strong>g the cl<strong>in</strong>icians who would be recruit<strong>in</strong>g patients <strong>in</strong>to the trial <strong>in</strong> recruitment<br />
strategies and procedures” and that “The protocol will be amended accord<strong>in</strong>gly. These <strong>in</strong>clude: Consider<br />
tra<strong>in</strong><strong>in</strong>g participant recruiters”.<br />
On 12 th May 2004 the Parliamentary Under Secretary of State at the Department of Health, Dr Stephen<br />
Ladyman, announced at an All Party Parliamentary Group on Fibromyalgia (FM) that doctors were be<strong>in</strong>g<br />
offered f<strong>in</strong>ancial <strong>in</strong>ducements to persuade patients with FM to attend a “CFS” Cl<strong>in</strong>ic to aid recruitment to<br />
the PACE Trial. For achievement of the recruitment target to have to depend on f<strong>in</strong>ancial <strong>in</strong>ducements to<br />
cl<strong>in</strong>icians <strong>in</strong> order to persuade patients who do not suffer from <strong>ME</strong>/CFS to enter the PACE Trial would<br />
seem to <strong>in</strong>dicate that someth<strong>in</strong>g is seriously wrong with the trial.<br />
With the aim of improv<strong>in</strong>g “generalisation of our results to a larger number of patients” as well as<br />
improv<strong>in</strong>g recruitment, by letter dated 9 th February 2006 to the West Midland MREC, Peter White<br />
requested changes to the eligibility and primary outcome criteria. He sought permission to change the SF‐<br />
36 threshold for <strong>in</strong>clusion (the <strong>Invest</strong>igators were hav<strong>in</strong>g to turn away patients because they were too well)<br />
and he sought permission to <strong>in</strong>clude patients who had previously received CBT/GET at non‐PACE Trial<br />
centres. What the consequences of allow<strong>in</strong>g an unspecified number of people who had previously<br />
received CBT/GET to jo<strong>in</strong> the PACE Trial might be was not clarified.<br />
By letter dated 14 th July 2006 to the West Midlands MREC, Peter White requested permission to advertise<br />
(his word) the PACE Trial to GPs. The <strong>Invest</strong>igators were really struggl<strong>in</strong>g to recruit participants so decided<br />
to recruit patients direct from primary care. The word<strong>in</strong>g of the advertisement to GPs is <strong>in</strong>terest<strong>in</strong>g: “If you<br />
have a patient with def<strong>in</strong>ite or probable CFS/<strong>ME</strong>, whose ma<strong>in</strong> compla<strong>in</strong>t is fatigue (or a synonym), please consider<br />
referr<strong>in</strong>g them to one of the PACE Trial centres”. Just how scientifically rigorous the <strong>in</strong>clusion of patients<br />
with “fatigue (or a synonym)” might be is a matter for speculation.<br />
Quite certa<strong>in</strong>ly, such broad canvass<strong>in</strong>g has resulted <strong>in</strong> someone who had sh<strong>in</strong>gles (herpes zoster) be<strong>in</strong>g<br />
<strong>in</strong>cluded <strong>in</strong> the PACE Trial on “CFS/<strong>ME</strong>”: s<strong>in</strong>ce the Oxford criteria catch anyone who is chronically<br />
“fatigued”, people with post‐herpetic tiredness are known to be <strong>in</strong>cluded <strong>in</strong> the PACE Trial, even though<br />
herpes zoster is not the same disorder as <strong>ME</strong>/CFS. Such lack of exactitude means that the results of the<br />
PACE Trial could be mean<strong>in</strong>gless.<br />
The PACE Participants’ Newsletter (Issue 2, March 2007) was openly solicit<strong>in</strong>g for more participants: “If you<br />
know of any friends or family who suffer from CFS/<strong>ME</strong> and who might be eligible and <strong>in</strong>terested <strong>in</strong> tak<strong>in</strong>g part <strong>in</strong> the<br />
study and live close enough to one of these centres, please suggest they approach their GP for a referral to a PACE<br />
centre”. The problems with us<strong>in</strong>g exist<strong>in</strong>g participants to recruit new participants are obvious.<br />
First, the exist<strong>in</strong>g participant might no longer feel <strong>in</strong>cl<strong>in</strong>ed to report negative effects and might exaggerate<br />
any positive effects because (i) they may feel they have become part of the PACE research team and thus feel<br />
a loyalty that could <strong>in</strong>fluence how they report their experience and (ii) participants who recruit others are<br />
ask<strong>in</strong>g them to jo<strong>in</strong> <strong>in</strong> their own experience and thus they assume a burden of responsibility, as a result of<br />
which they may be less likely to report ‘it was awful’ or ‘ it did not help’. This could render their own<br />
subjective data <strong>in</strong>valid. Furthermore, if a participant knows s/he has persuaded someone else to jo<strong>in</strong> the